When to base clinical policies on observational versus randomized trial data

Annals of Internal Medicine

Volumn 127, Issue 8 II SUPPL., 1997, Pages 697-703

  Hornberger, John ^a   Wrone, Elizabeth ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; DATA BASE; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; INFORMATION SYSTEM; PRIORITY JOURNAL;

EID: 0030846060     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-127-8_part_2-199710151-00053     Document Type: Conference Paper

References (57)

1. Carey RG, Lloyd RC. Measuring Quality Improvement in Health Care. A Guide to Statistical Process Control Applications. New York: Quality Resources; 1997.
2. Lamas GA, Pfeffer MA, Hamm P, Wertheimer J, Rouleau JL, Braunwald E. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators. N Engl J Med. 1992;327:241-7.
3. Moss AJ, Davis HT, Conrad DL, DeCamilla JJ, Odoroff CL. Digitalis-associated cardiac mortality after myocardial infarction. Circulation. 1981;64:1150-6.
4. Madsen EB, Gilpin E, Henning H, Ahnve S, LeWinter M, Mazur J, et al. Prognostic importance of digitalis after acute myocardial infarction. J Am Coll Cardiol 1984;3:681-9.
5. Ryan TJ, Bailey KR, McCabe CH, Luk S, Fisher LD, Mock MB, et al. The effects of digitalis on survival in high-risk patients after coronary artery disease. The Coronary Artery Surgery Study (CASS). Circulation. 1983;67:735-42.
6. Yusuf S, Wittes J, Bailey K, Furberg C. Digitalis - a new controversy regarding an old drug. The pitfalls of inappropriate methods. Circulation. 1986;73:14-8.
7. Byar DP. Problems with using observational databases to compare treatments. Stat Med. 1991;10:663-6.
8. Byar DP. Why data bases should not replace randomized trial Biometrics. 1980;36:337-41.
9. Lavori PW, Louis TA, Bailar JC III, Polansky M. Designs for experiments Parallel comparisons of treatments. In: Bailar JC III, Mosteller F, eds. Medical Uses of Statistics. Waltham, MA: NEJM Books; 1986:41-66.
10. Rubin DB. Bayesian inference for causal effects: the role of randomization. Ann Stat. 1978;6:34-58.
11. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med. 1997;336:525-33.
12. Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med. 1993;329:1-7.
13. Uretsky BR, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure. J Am Coll Cardiol. 1993;22:955-62.
14. Blumberg J, Block G. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study in Finland. Nutr Rev. 1994;52:242-5.
15. van Poppel G. Carotenoids and cancer: an update with emphasis on human intervention studies. Eur J Cancer. 1993;29A:1335-44.
16. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group. N Engl J Med. 1994;330:1029-35.
17. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1997;334:1145-9.
18. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1997;334:1150-5.
19. Greenberg ER, Sporn MB. Antioxidant vitamins, cancer, and cardiovascular disease. N Engl J Med. 1996;334:1189-90.
20. Moses LE. Measuring effects without randomized trials? Options, problems, challenges. Med Care. 1996;33(4 Suppl):AS8-14.
21. Moses LE, Mosteller F. Experimentation: just do it! In: Spencer BD, ed. Statistics and Public Policy. Oxford: Oxford Univ Pr; 1997:212-32.
22. Committee for Evaluating Medical Technologies in Clinical Use, Division of Health Sciences Policy, Division of Health Promotion and Disease Prevention, Institute of Medicine. Assessing Medical Technologies. Washington, DC: National Academy Pr; 1985.
23. Gilbert JP, McPeek B, Mosteller F. Progress in surgery and anesthesia: benefits and risks of innovative therapy. In: Mosteller F, ed. Costs, Risks, and Benefits of Surgery. New York: Oxford Univ Pr; 1977:124-69.
24. Kadane JB. Bayesian Methods and Ethics in a Clinical Trial Design. New York: J Wiley; 1996.
25. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol. 1996;27:517-27.
26. Chauveau P, Chadefaux B, Coude M, Aupetit J, Hannedouche T, Kamoun P, et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremia patients. Kidney Int Suppl. 1993;41:S72-7.
27. Bostom AG, Shemin D, Ladane KL, Miller JW, Sutherland P, Nadeau M, et al. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis. 1995;114:93-103.
28. U.S. Renal Data System. Annual Data Report. Bethesda, MD: The National Institutes of Health, The National Institute of Diabetes and Digestive and Kidney Diseases; 1996.
29. Landgren F, Israelsson B, Lindren M, Huttberg B, Andersson A, Brattstrom L. Plasma homocysteine in acute myocardial infarction: homocysteine lowering effect of folic acid. J Intern Med. 1995;237:381-8.
30. Arnodattir M, Brattstrom L, Simonsen O, Thysell H, Hultberg B, Anderson A, et al. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol. 1993;40:236-40.
31. Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau MR, et al. High-dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int. 1996;49:147-52.
32. Weinstein MC, Fineberg HV. Clinical Decision Analysis. Philadelphia: WB Saunders; 1980.
33. Gold MR, Siegel J, Russell L, Weinstein M, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford Univ Pr; 1997.
34. Eisenberg JM. Clinical economics: a guide to the economic analysis of clinical practice. JAMA. 1989;262:2879-86.
35. Fuchs VR, Garber AM. The new technology assessment. N Engl J Med. 1990;323:673-7.
36. Hornberger JC, Brown BW, Halpern J. Designing a cost-effective clinical trial. Stat Med. 1995;14:2249-59.
37. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 1992;146:473-81.
38. Hornberger JC. The hemodialysis prescription and quality-adjusted life expectancy. Renal Physicians Association Working Committee on Clinical Guidelines. J Am Soc Nephrol. 1993;4:1004-20.
39. Robert CP. The Bayesian Choice: A Decision-Theoretic Motivation. New York: Springer-Verlag; 1994.
40. Berger JO. Statistical Decision Theory and Bayesian Analysis. 2d ed. New York: Springer-Verlag; 1986.
41. Brophy JM, Joseph L. Placing trials in context using Bayesian analysis: GUSTO revisited by Reverend Bayes. JAMA. 1995;273:871-5.
42. Detsky AS. Using cost-effectiveness analysis to improve the efficiency of allocating funds to clinical trials. Stat Med. 1990;9:173-84.
43. Bernardo JM, Smith AF. Bayesian Theory. Chichester, MA: J Wiley; 1994.
44. Berry DA, Stangl DK. Bayesian Biostatistics. New York: Marcel Dekker; 1996.
45. Matheson JE, Howard RA. An introduction to decision analysis. In: Howard RA, Matheson JE, eds. The Principles and Applications of Decision Analysis. Volume I: General Collection. Palo Alto, CA: Strategic Decisions Group; 1968:17-56.
46. Detsky AS. Are clinical trials a cost-effective investment? JAMA. 1989;262:1795-800.
47. Berry DA. Bayesian methodology in phase III trials. Drug Information Association Journal. 1991;25:345-68.
48. Colton T. A model for selecting one of two medical treatments. Journal of the American Statistical Association. 1963:388-400.
49. Canner PL. Selecting one of two treatments when the responses are dichotomous. Journal of the American Statistical Association. 1970;65:293-306.
50. Hornberger JC. Cost-benefit of a disease prevention trial: folate as an example. Am J Public Health. 1997; [In press].
51. Sylvester RJ. A Bayesian approach to the design of phase II clinical trials. Biometrics. 1988;44:823-36.
52. Sylvester RJ. Reply to comments on "A Bayesian approach to the design of phase II clinical trials." Biometrics [Letter] 1990;46:537-8.
53. Weinstein MC. Cost-effective priorities for cancer prevention. Science. 1983;221:17-23.
54. The Department of Ambulatory Care and Prevention of Harvard Pilgrim Health Care. HMO Research Network Conference. Cambridge, MA; 1997.
55. Shortliffe EH. Clinical decision-support systems. In: Shortliffe EH, Perreault LE, Wiederhold G, Fagan LM, eds. Medical Informatics: Computer Applications in Health Care. Reading, MA: Addison-Wesley; 1990:466-502.
56. Brown BW Jr. The randomized clinical trial. Stat Med. 1984;3:307-14.
57. Pearson SD, Goulart-Fisher D, Lee TH. Critical pathways as a strategy for improving care: problems and potential. Ann Intern Med. 1995;123:941-8.